Open Access Full Text Article


CORRIGENDUM

Targeting PIK3CG in Combination with Paclitaxel as a Potential Therapeutic Regimen in Claudin-Low Breast Cancer [Corrigendum]

Chang J, Hong L, Liu Y. Cancer Manag Res. 2020;12:2641–2651.

The authors apologize for this error.

The authors have advised that there is an error in Figure 2E on page 2646. The correct figure is shown below.



Cancer Management and Research 2020:12 3331-3332

333 I

DovePress in http://doi.org/10.2147/CMAR.5260280

submit your manuscript

© 2020 Chang et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms. work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission for Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).

Cancer Management and Research

Publish your work in this journal

Cancer Management and Research is an international, peer-reviewed open access journal focusing on cancer research and the optimal use of preventative and integrated treatment interventions to achieve improved outcomes, enhanced survival and quality of life for the cancer patient. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.

Submit your manuscript here: https://www.dovepress.com/cancer-management-and-research-journal

Dovepress